Zymeworks will pay $17.00/share (~$929M) for Theravance, prioritizing Yupelri-linked profitability and planned post-close ...

Ryan Last, senior associate at Troutman Pepper Locke explains how existing regulations and potential foreign countermeasures have a significant impact on reshoring efforts. In today's Pharmaceutical ...

Troutman Pepper Locke senior associate Ryan Last explains when markets will start to significantly react to the upcoming pharma tariffs. In April of this year, President Trump announced plans to ...

It was a jarring experience that stemmed from a startlingly common misconception: that adults don't get T1D; however, she is ...

Pharmaceutical Executive | Publications | Pharmaceutical Executive delivers strategic insights for pharma leaders, covering commercialization, market access, R&D, and leadership to drive success.

In today's Pharmaceutical Executive Daily, AbbVie announces a $10.9 billion agreement to acquire Apogee Therapeutics, adding ...

In today's Pharmaceutical Executive Daily, a pharma M&A roundup covers Ipsen's up to $1.75 billion acquisition of Kartos Therapeutics and Zymeworks' $929 million acquisition of Theravance Biopharma, ...

FDA selected seven participants from 80+ requests using a scoring rubric emphasizing supply need, facility development stage, time-to-market, and manufacturing innovation. Amneal will make sterile ...

Pharmaceutical Executive: How will targeted onshoring impact pharma’s domestic manufacturing? Ryan Last: Targeted reshoring ...

In today's Pharmaceutical Executive Daily, the FDA approves Gilead's Trodelvy for the first-line treatment of metastatic ...

Resilient field models emphasize continuous territory coverage via agile deployment, blending scalable virtual reach with ...

For pharmaceutical executives, the transition from just extending to fully optimizing life is a defining commercial ...